Next-Gen CAR Delivery-Toward Off-the-Shelf CAR Therapies: Targeted In Vivo Lentiviral Delivery to T and NK Cells

Recently, researchers introduced a groundbreaking lentiviral platform designed to enable the in vivo delivery of stably integrating genetic medicines directly to T and NK cells, eliminating the need for traditional lymphodepleting chemotherapy. This platform utilizes a novel detargeted viral fusogen and a cell-specific targeting moiety to achieve precise delivery, offering a less invasive and more streamlined approach to cellular engineering. By bypassing the complexities of ex vivo cell manipulation and conditioning regimens, this technology holds the potential to make CAR-based therapies significantly more accessible, paving the way for off-the-shelf treatments that can reach a broader patient population.

SHARE

Related Post

Fascinating advances in time-resolved structural biology

Researchers from the University of Oxford, SLAC National Accelerator Laboratory, and Lawrence...

From A Single Protein to a Revolution in Neuroscience

This year’s Nobel Prize in Physiology or Medicine recognizes Karl Deisseroth, Peter...

GOOSE: Understanding and Designing Intrinsically Disordered Protein

We often read papers about the three-dimensional (3D) structures of proteins, particularly...